GLP

R&D

New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into force in February next year.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.